Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7405208 | 0.95 | GPR119 (0.52) | GPR119FAAHKDM4EPKMMAPT | |
| SCHEMBL1575979 | 0.89 | GPR119 (0.53) | GPR119FAAHKDM4EPKMKMT2A | |
| SCHEMBL1575876 | 0.87 | GPR119 (0.53) | GPR119FAAHKDM4EPKM | |
| SCHEMBL1576241 | 0.85 | KDM4E (0.51) | GPR119FAAHKDM4EPKM | |
| SCHEMBL1575509 | 0.85 | KDM4E (0.51) | GPR119FAAHKDM4EPKMKMT2A | |
| SCHEMBL31752872 | 0.85 | CHEK2 (0.56) | GPR119FAAHKDM4EPKM | |
| SCHEMBL1575733 | 0.84 | GPR119 (0.72) | GPR119FAAHKDM4EPKM | |
| SCHEMBL7400403 | 0.84 | GPR119 (0.51) | GPR119FAAHKDM4EPKMMAPT | |
| SCHEMBL1575819 | 0.83 | GPR119 (0.57) | GPR119FAAH | |
| SCHEMBL1575706 | 0.83 | GPR119 (0.74) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172358-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172358-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20100063081-A1 | CPCR Agonists | PROSIDION LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063081-A1 | CPCR Agonists | PROSIDION LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| WO-2007003962-A2 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172358-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885FAAH 295/4885KDM4E 3925/4885 |
| US-20100063081-A1 | CPCR Agonists | GPR119, GCGR, GLP1R | GPR119 1/4885FAAH 605/4885KDM4E 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.